Vietnamese Patent Granted for RECCE Anti-Infectives
Open PDF
| Stock | Recce Pharmaceuticals Ltd (RCE.ASX) |
|---|---|
| Release Time | 14 Jul 2026, 8:56 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Recce Pharmaceuticals Granted Vietnamese Patent for Anti-Infectives
Key Points
- Recce Pharmaceuticals granted Family 4 patent in Vietnam for RECCE 327 and RECCE 529
- Patent covers process for preparation and treatment of various infections
- Vietnam faces high rates of antibiotic resistance, reinforcing need for new therapies
Full Summary
Recce Pharmaceuticals Ltd, a developer of synthetic anti-infectives, has been granted a Family 4 patent by the Intellectual Property Office of Vietnam for RECCE 327 and RECCE 529. The patent covers the preparation process and use of these compounds for treating bacterial and viral infections. This milestone strengthens Recce's intellectual property portfolio and positions it strategically in Vietnam, a rapidly growing pharmaceutical market facing significant antimicrobial resistance challenges.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In